Skip to content

PRA023 for Systemic Sclerosis with Interstitial Lung Disease

Search Clinical Trials

Trial Objectives

Researchers are studying a new medication called PRA023 that has anti-inflammatory and antifibrotic properties to determine how well it works against systemic sclerosis (SSc) with interstitial lung disease (ILD). The goal of this study is to understand how safe and effective PRA023 is as a treatment option as compared to a placebo (an inactive substance that looks the same and is administered the same way as PRA023) for people for diagnosed with SSc-ILD. Study participants will receive monthly IV infusions and breathing tests, along with other assessments. If eligible, participants also may enter an open label extension for another 50 weeks, where they will receive active PRA023.

Who Can Participate

People with a confirmed diagnosis of Systemic Sclerosis (SSc) with SSc-related Interstitial Lung Disease (ILD)

Age: 18+ Gender: Any

Estimated Time Commitment

Monthly visits over 50-week timeframe

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Cynthia Wainscoat

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Prometheus Biosciences

Principal Investigators

Mehrnaz Maleki Fischbach

Mehrnaz Maleki Fischbach, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required